



## **Health Insurance (Section 3C Co-Dependent Pathology Services) Amendment Determination (No. 2) 2022**

---

I, Nigel Murray, delegate of the Minister for Health and Aged Care, make the following Determination.

Dated                30 March 2022

Nigel Murray  
Assistant Secretary  
MBS Policy and Specialist Services Branch  
Medical Benefits Division  
Health Resourcing Group  
Department of Health

---



---

## Contents

1 Name.....	1
2 Commencement .....	1
3 Authority .....	1
4 Schedules .....	1
<b>Schedule 1— Amendments.....</b>	<b>2</b>



---

## 1 Name

This instrument is the *Health Insurance (Section 3C Co-Dependent Pathology Services) Amendment Determination (No. 2) 2022*.

## 2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. The whole of this instrument	1 April 2022	

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

## 3 Authority

This instrument is made under subsection 3C(1) of the *Health Insurance Act 1973*.

## 4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

---

## Schedule 1— Amendments

### *Health Insurance (Section 3C Co-Dependent Pathology Services) Determination 2018*

#### 1. Schedule 1 (after item 73302)

Insert:

73303	A test of tumour tissue from a patient with metastatic castration-resistant prostate cancer, including subsequent characterisation of germline gene variants should tumour tissue testing undertaken during the same service be inconclusive, requested by a specialist or consultant physician, to determine eligibility relating to <i>BRCA</i> status for access to olaparib under the Pharmaceutical Benefits Scheme;  Applicable once per primary tumour diagnosis	1,000.00
73304	Detection of germline <i>BRCA1</i> or <i>BRCA2</i> pathogenic or likely pathogenic gene variants, in a patient with metastatic castration-resistant prostate cancer, for whom testing of tumour tissue is not clinically feasible, requested by a specialist or consultant physician, to determine eligibility for olaparib under the Pharmaceutical Benefits Scheme;  Applicable once per lifetime	1,000.00

---